Armed with results from a phase 2 trial, Boehringer Ingelheim has said it will take its obesity drug candidate survodutide into a phase 3 programme later this year. The glucagon/GLP-1 receptor dual ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage ...

Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand), showed efficacy in adults with active systemic lupus erythematosus (SLE) ...

ABB, Eaton, and NVIDIA are advancing the next phase of AI power infrastructure, collaborating on 800-V DC architectures to support megawatt-class racks and gigawatt-scale ...

Enphase Energy Inc. (ENPH) reported its Q2 2025 earnings, showcasing robust product innovation and solid financial performance. The company achieved a revenue of $363.2 million and a non-GAAP EPS of ...

Binding commitments were made for the placement of 133.3m shares which includes one free attaching option exercisable at 6.5c and expiring on October 31, 2028. “We are encouraged by the strong market ...